Mefenorex

Nowadays, Mefenorex has become a topic of great relevance in our society. Since its origins, Mefenorex has generated growing interest among researchers, academics and the general public. Its impact has been reflected in different areas, from culture to the economy, including politics and the environment. In this article, we will explore in depth the importance of Mefenorex, its evolution over time and its influence on our daily lives. In addition, we will analyze the different perspectives and opinions that exist around Mefenorex, in order to better understand its scope and consequences.

Mefenorex
Clinical data
Trade namesRondimen, Pondinil, Anexate
ATC code
Legal status
Legal status
Identifiers
  • 3-chloro-N-(1-methyl-2-phenylethyl)propan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.037.511 Edit this at Wikidata
Chemical and physical data
FormulaC12H18ClN
Molar mass211.73 g·mol−1
3D model (JSmol)
  • ClCCCNC(Cc1ccccc1)C
  • InChI=1S/C12H18ClN/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12/h2-4,6-7,11,14H,5,8-10H2,1H3 checkY
  • Key:XXVROGAVTTXONC-UHFFFAOYSA-N checkY
  (verify)

Mefenorex is a central nervous system (CNS) stimulant drug of the phenethylamine and amphetamine chemical classes, developed in the 1970s as an anti-obesity medication and appetite suppressant, and marketed Rondimen, Pondinil, and Anexate, indicated for the treatment of obesity and promoting weight loss.

Mefenorex has milder stimulating effects than most amphetamines (e.g. methamphetamine, racemic amphetamine, and dextroamphetamine) as well as most "amphetamine-like" anorectics (e.g. phenmetrazine, phendimetrazine, phentermine); in conjunction with a relatively mild abuse, dependency, and addiction liability (perhaps most similar to fenproporex or sibutramineboth also amphetamine derivatives), it is uncertain why the product and its branded formulation have been discontinued from production and withdrawn from the market of most countries since the 1980s."[2]marketed (in common parlance, "diet pill") to treatment of obesity in patients.[3][4]

Mefenorex is a prodrug of racemic racemic amphetamine, which is a balanced, one-to-one (1:1) mixture of 50% levoamphetamine and 50% dextroamphetamine; upon ingesting the substance, the consumer's body will begin to "metabolize, or "break down" the substance into active metabolites, in this case, both D-amphetamine as well as D-amphetamine, albeit in a steady, extended-release timeframe.[5]

References

  1. ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  2. ^ Engel J, Kristen G, Schaefer A, von Schlichtegroll A (June 1986). "Mefenorex (Rondimen)". Drug and Alcohol Dependence. 17 (2–3): 229–34. doi:10.1016/0376-8716(86)90010-4. PMID 3743406.
  3. ^ Vincendeau MJ (1970). "". Bordeaux Medical (in French). 3 (7): 1951–3. PMID 5455004.
  4. ^ Beyer G, Huth K, Müller GM, Niemöller H, Raisp I, Vorberg G (February 1980). "". Die Medizinische Welt (in German). 31 (8): 306–9. PMID 7374423.
  5. ^ Rendić S, Slavica M, Medić-Sarić M (1994). "Urinary excretion and metabolism of orally administered mefenorex". European Journal of Drug Metabolism and Pharmacokinetics. 19 (2): 107–17. doi:10.1007/BF03188831. PMID 8001591. S2CID 7170057.

See also


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.